CA2234967A1 - Fibrinogen receptor antagonists - Google Patents
Fibrinogen receptor antagonists Download PDFInfo
- Publication number
- CA2234967A1 CA2234967A1 CA002234967A CA2234967A CA2234967A1 CA 2234967 A1 CA2234967 A1 CA 2234967A1 CA 002234967 A CA002234967 A CA 002234967A CA 2234967 A CA2234967 A CA 2234967A CA 2234967 A1 CA2234967 A1 CA 2234967A1
- Authority
- CA
- Canada
- Prior art keywords
- ethyl
- alkyl
- acetyl
- alanine
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US560295P | 1995-10-19 | 1995-10-19 | |
US60/005,602 | 1995-10-19 | ||
GB9603371.7 | 1996-02-16 | ||
GBGB9603371.7A GB9603371D0 (en) | 1996-02-16 | 1996-02-16 | Fibrinogen receptor antagonists |
PCT/US1996/016491 WO1997014417A1 (en) | 1995-10-19 | 1996-10-15 | Fibrinogen receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2234967A1 true CA2234967A1 (en) | 1997-04-24 |
Family
ID=26308744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002234967A Abandoned CA2234967A1 (en) | 1995-10-19 | 1996-10-15 | Fibrinogen receptor antagonists |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0866705A4 (de) |
JP (1) | JPH11513686A (de) |
AU (1) | AU713247B2 (de) |
CA (1) | CA2234967A1 (de) |
WO (1) | WO1997014417A1 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5889023A (en) * | 1996-05-10 | 1999-03-30 | Merck & Co., Inc. | Fibrinogen receptor antagonist |
US6194435B1 (en) | 1996-10-11 | 2001-02-27 | Cor Therapeutics, Inc. | Lactams as selective factor Xa inhibitors |
US6369080B2 (en) | 1996-10-11 | 2002-04-09 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
US6262047B1 (en) | 1996-10-11 | 2001-07-17 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
US6063794A (en) | 1996-10-11 | 2000-05-16 | Cor Therapeutics Inc. | Selective factor Xa inhibitors |
JP2001521524A (ja) * | 1997-04-14 | 2001-11-06 | シーオーアール セラピューティクス インコーポレイテッド | 選択的Xa因子阻害剤 |
WO1998046627A1 (en) | 1997-04-14 | 1998-10-22 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS |
JP2001523226A (ja) | 1997-04-14 | 2001-11-20 | シーオーアール セラピューティクス インコーポレイテッド | 選択的Xa因子阻害剤 |
EP0975625A1 (de) | 1997-04-14 | 2000-02-02 | Cor Therapeutics, Inc. | AUSWÄHLEND Xa KAKTOR INHIBITOREN |
US6333321B1 (en) | 1997-08-11 | 2001-12-25 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
US6228854B1 (en) | 1997-08-11 | 2001-05-08 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
US6218382B1 (en) | 1997-08-11 | 2001-04-17 | Cor Therapeutics, Inc | Selective factor Xa inhibitors |
EP1080075B1 (de) * | 1998-03-23 | 2004-08-11 | Aventis Pharmaceuticals Inc. | Piperidinyl- und n-amidinopiperidinyl-derivate |
US6344450B1 (en) | 1999-02-09 | 2002-02-05 | Bristol-Myers Squibb Company | Lactam compounds and their use as inhibitors of serine proteases and method |
EP1156803A4 (de) | 1999-02-09 | 2004-03-17 | Bristol Myers Squibb Co | LACTAM INHIBITOREN DES FXa UND METHODE |
US6645968B2 (en) | 1999-08-03 | 2003-11-11 | Abbott Laboratories | Potassium channel openers |
TWI288745B (en) | 2000-04-05 | 2007-10-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
US7225170B1 (en) | 2000-07-27 | 2007-05-29 | Pitney Bowes Inc. | Postage metering system for use with business reply mail |
US6511973B2 (en) | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
HUP0304058A2 (hu) | 2001-01-30 | 2004-04-28 | Bristol-Myers Squibb Company | Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
KR100966749B1 (ko) | 2004-05-26 | 2010-06-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물 |
CN100577657C (zh) | 2004-10-26 | 2010-01-06 | 卫材R&D管理有限公司 | 肉桂酰胺化合物的无定形物 |
AU2006316005A1 (en) * | 2005-11-18 | 2007-05-24 | Eisai R & D Management Co., Ltd. | Process for production of cinnamamide derivative |
JP2009525269A (ja) * | 2006-01-30 | 2009-07-09 | ユーロ−セルティーク エス.エイ. | カルシウムチャネルブロッカーとしての環状尿素化合物 |
TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
TW200848054A (en) | 2007-02-28 | 2008-12-16 | Eisai R&D Man Co Ltd | Two cyclic oxomorpholine derivatives |
US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
AR068121A1 (es) | 2007-08-31 | 2009-11-04 | Eisai R&D Man Co Ltd | Compuestos multiciclicos para tratar enfermedades neurodegenerativas |
US8207155B2 (en) | 2009-03-31 | 2012-06-26 | Vanderbilt University | Sulfonyl-azetidin-3-yl-methylamine amide analogs as GlyTl inhibitors, methods for making same, and use of same in treating psychiatric disorders |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5037808A (en) * | 1988-07-20 | 1991-08-06 | Monsanto Co. | Indolyl platelet-aggregation inhibitors |
US5039805A (en) * | 1988-12-08 | 1991-08-13 | Hoffmann-La Roche Inc. | Novel benzoic and phenylacetic acid derivatives |
US5051405A (en) * | 1989-10-10 | 1991-09-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Anti-thrombotic peptides and pseudopeptides |
NZ239876A (en) * | 1990-09-27 | 1993-12-23 | Merck & Co Inc | Glycyl-b-alanine derivatives and pharmaceutical compositions thereof. |
IL99537A (en) * | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical preparations containing them |
HUT68769A (en) * | 1991-05-07 | 1995-07-28 | Merck & Co Inc | FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE |
US5321034A (en) * | 1991-05-07 | 1994-06-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5272158A (en) * | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5416099A (en) * | 1991-10-29 | 1995-05-16 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
CA2144762A1 (en) * | 1992-10-14 | 1994-04-28 | George D. Hartman | Fibrinogen receptor antagonists |
US5648368A (en) * | 1992-12-01 | 1997-07-15 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
WO1995025101A1 (en) * | 1994-03-14 | 1995-09-21 | Merck & Co., Inc. | Pyridil ethylation of lactams |
WO1995025088A1 (en) * | 1994-03-14 | 1995-09-21 | Merck & Co., Inc. | Pyridyl ethylation of lactam derivatives |
WO1996019221A1 (en) * | 1994-12-22 | 1996-06-27 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
-
1996
- 1996-10-15 WO PCT/US1996/016491 patent/WO1997014417A1/en not_active Application Discontinuation
- 1996-10-15 CA CA002234967A patent/CA2234967A1/en not_active Abandoned
- 1996-10-15 AU AU74322/96A patent/AU713247B2/en not_active Ceased
- 1996-10-15 JP JP9515931A patent/JPH11513686A/ja active Pending
- 1996-10-15 EP EP96936505A patent/EP0866705A4/de not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU713247B2 (en) | 1999-11-25 |
EP0866705A4 (de) | 1999-03-03 |
WO1997014417A1 (en) | 1997-04-24 |
JPH11513686A (ja) | 1999-11-24 |
EP0866705A1 (de) | 1998-09-30 |
AU7432296A (en) | 1997-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2234967A1 (en) | Fibrinogen receptor antagonists | |
AU712082B2 (en) | Fibrinogen receptor antagonists | |
AU719102B2 (en) | Fibrinogen receptor antagonist prodrugs | |
AU721130B2 (en) | Fibrinogen receptor antagonists | |
US5854245A (en) | Fibrinogen receptor antagonists | |
US5719162A (en) | Fibrinogen receptor antagonists | |
AU713676B2 (en) | Integrin receptor antagonists | |
US5780480A (en) | Fibrinogen receptor antagonists | |
US5932582A (en) | Fibrinogen receptor antagonist prodrugs | |
US5852045A (en) | Fibrinogen receptor antagonists | |
US5952306A (en) | Integrin receptor antagonists | |
US6544982B1 (en) | Thrombin receptor antagonists | |
AU689961B2 (en) | Fibrinogen receptor antagonists | |
AU742197B2 (en) | Fibrinogen receptor antagonists | |
US5525617A (en) | Fibrinogen receptor antagonists | |
US5789421A (en) | Fibrinogen receptor antagonist | |
AU702025B2 (en) | Fibrinogen receptor antagonist | |
US5889023A (en) | Fibrinogen receptor antagonist | |
GB2312895A (en) | Fibrinogen receptor antagonists | |
CZ317697A3 (cs) | Inhibitory agregace krevních destiček obsahující C-koncový postranní aminergní řetězec zbytků aminokyselin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |